Develops and sells veterinary medicines and pet/livestock health products worldwide.
Develops and sells veterinary medicines and pet/livestock health products worldwide.
Sells prescription and over-the-counter animal medicines through distributors, and vets decide what pet owners buy, so relationships with vets drive sales. Companion-animal products, such as vaccines and parasite treatments, carry more weight than livestock products, and sales spread across Europe, Asia-Pacific and the US.
Moat: narrow (IP / patents, regulatory licence, distribution). Regulatory approvals and established veterinary distribution relationships create moderate barriers to entry.
Headquarters: Carros, France · Founded: 1968 · Employees: 6,442
Size Virbac (VIRP.PA) is a France Health Care company (Biotechnology) with a market value of $3.20B, the 83rd largest of 206 France companies the cockpit tracks. Shares closed at €348.00 on 18 Nov 2026.
Performance Over six months the shares fell 4.3%, against +5.5% for the median peer and -2.1% for the France market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +8.9%); the operating margin is 15.1% (peer median -3.2%).
Valuation It trades at 16.6× forward earnings against a peer median of 31.3× (2nd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.4 points above its cost of capital (8.5% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.49B | €1.46B | €1.40B | €1.25B | €1.22B |
| Revenue growth | — | +5% | +12% | +3% | — |
| Gross profit | €532M | €518M | €501M | €423M | €427M |
| EBITDA | €289M | €277M | €275M | €220M | €219M |
| Net income | €156M | €151M | €145M | €121M | €122M |
| Free cash flow | €127M | €103M | €131M | €77.9M | €60.2M |
| Capital expenditure | €106M | €102M | €80.4M | €59.9M | €53.6M |
| Total debt | n/a | €291M | €308M | €121M | €91.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Virbac VIRP.PA | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Elanco Animal Health ELAN | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% |
| Vetoquinol VETO.PA | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
| Phibro Animal Health PAHC | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIRP.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -5.6% | 5th highest of 21 |
| 6-month return | -4.3% | +5.5% | 8th lowest of 21 |
| Distance from 52-week high | -10.7% | -29.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +4.3% | +8.9% | 8th lowest of 17 |
| Operating margin | 15.1% | -3.2% | 6th highest of 17 |
| Forward P/E | 16.6× | 31.3× | 2nd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 5.8% | 2.2% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +9.4% | +27.4% | 2nd lowest of 6 |
| Hurdle (Req g minus delivered) | -3.6 pp | -31.7 pp | 2nd most demanding of 6 |
| ROIC minus cost of capital | +3.4 pp | -9.4 pp | 4th highest of 16 |
| EV / EBITDA | 10.8× | 53.7× | 2nd cheapest of 6 |
| Net debt / EBITDA | 0.7× | 1.0× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 29.4× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |